The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Gene 52

Gene Hormones DNA Medicine 52

Roots Analysis

SEPTEMBER 9, 2024

Protein expression is a potent technology in the field of synthetic biology, that is utilized for the high-throughput production of proteins as well as enzymes and oligonucleotides (DNA / RNA). This process initially involves transcription of DNA to messenger RNA (mRNA). The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

XTalks

JUNE 20, 2022

Hereditary ATTR has an autosomal dominant pattern of inheritance and is caused by point mutations in the transthyretin ( TTR ) gene that codes for the transthyretin transport protein found in the plasma and cerebrospinal fluid. These abnormalities can lead to progressive heart failure and death. type transthyretin (TTR) messenger RNA (mRNA).

FDA Approval 98

FDA Approval Protein Genetics RNA 98

Find Me Cure

OCTOBER 13, 2019

CDK4/6 inhibitors are used alongside hormone therapy. PI3 kinase is an enzyme controlled by the PIK3CA gene, a gene that is often mutated in breast cancer, which in turn causes the cancerous tumour to grow. . An enzyme involved in DNA repair can be the key to making chemotherapy more effective.

Development 52

Development DNA Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 24, 2021

The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).

DNA 52

DNA Clinical Trials Clinical Trials Trials 52

The Pharma Data

MARCH 22, 2021

Radioligand therapy combines a targeting compound that binds to markers expressed by tumors and a radioactive isotope, causing DNA damage that inhibits tumor growth and replication. In metastatic CRPC (mCRPC), the tumor spreads to other parts of the body, such as neighboring organs or bones and remains unresponsive to hormone treatment 4.

Hormones 52

Hormones Gene Therapy Medicine Trials 52

The Pharma Data

APRIL 11, 2023

Another key focus at Bayer is on innovative precision oncology treatments, with an approved TRK inhibitor exclusively designed to treat tumors that have an NTRK gene fusion, the oncogenic driver of tumor growth and spread.

Research 40

Research Clinical Trials Clinical Trials Trials 40

The Pharma Data

APRIL 7, 2023

Inhibition of PARP with Lynparza leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.

Trials 40

Trials DNA Medicine Development 40

XTalks

DECEMBER 22, 2021

The gene-editing tool CRISPR edits DNA using specialized strands of guide RNA and endogenous cellular mechanisms of RNA interference. They can provide continuous real-time monitoring of metabolites, bacteria, hormones, glucose and other elements in these fluids. Minimally Invasive Devices.

Life Science 98

Life Science RNA Vaccination Vaccine 98

XTalks

FEBRUARY 5, 2024

It represents the inaugural targeted therapy designed to impede the DNA damage response (DDR) in cells or tumors exhibiting a deficiency in homologous recombination repair (HRR), notably those with mutations in BRCA1 and/or BRCA2 or those where deficiency is induced by other agents, such as DNA-damaging chemotherapies.

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

FEBRUARY 5, 2024

It represents the inaugural targeted therapy designed to impede the DNA damage response (DDR) in cells or tumors exhibiting a deficiency in homologous recombination repair (HRR), notably those with mutations in BRCA1 and/or BRCA2 or those where deficiency is induced by other agents, such as DNA-damaging chemotherapies.

FDA Approval 52

FDA Approval Drugs Sales Development 52

The Pharma Data

JANUARY 21, 2021

The test valuates mitochondrial DNA levels. When mitochondrial DNA, normally found inside cells, in the mitochondria, spills into the bloodstream, it signals that a particular type of violent cell death is occurring. They measured the patients’ mitochondrial DNA levels on the first day of their hospital stays.

Research 52

Research DNA Hormones Vaccination 52

XTalks

FEBRUARY 27, 2025

The trial was conducted on patients whose tumors have developed mutations in the estrogen receptor 1 ( ESR1 ) gene, a known contributor to endocrine therapy resistance that leads to relapses and rapid disease progression, limiting treatment options and worsening survival prospects.

Trials 59

Trials HR Clinical Trials Clinical Trials 59